MY113489A - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
MY113489A
MY113489A MYPI96001076A MYPI19961076A MY113489A MY 113489 A MY113489 A MY 113489A MY PI96001076 A MYPI96001076 A MY PI96001076A MY PI19961076 A MYPI19961076 A MY PI19961076A MY 113489 A MY113489 A MY 113489A
Authority
MY
Malaysia
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
specific
Prior art date
Application number
MYPI96001076A
Inventor
Lee Klaus Jeffrey
T Palmer James
Rasnick David
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of MY113489A publication Critical patent/MY113489A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

THE INVENTION RELATES TO NOVEL REVERSIBLE PROTEASE. THE INHIBITORS ARE SPECIFIC TO CYSTEINE PROTEASES.
MYPI96001076A 1995-03-24 1996-03-22 Reversible protease inhibitors MY113489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
MY113489A true MY113489A (en) 2002-03-30

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI96001076A MY113489A (en) 1995-03-24 1996-03-22 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (en)
JP (1) JPH11503417A (en)
KR (1) KR19980703261A (en)
CN (1) CN1071751C (en)
AU (1) AU713492B2 (en)
CA (1) CA2216151A1 (en)
CZ (1) CZ298197A3 (en)
IL (1) IL117638A0 (en)
MY (1) MY113489A (en)
NO (1) NO311573B1 (en)
NZ (1) NZ305626A (en)
PL (1) PL322409A1 (en)
TW (1) TW470750B (en)
WO (1) WO1996030353A1 (en)
ZA (1) ZA962336B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0912601T4 (en) 1996-04-22 2009-03-09 Massachusetts Inst Technology Suppression of immune response by inhibition of cathepsin S
NZ333713A (en) * 1996-07-30 2000-12-22 Axys Pharm Inc Compounds for treating diseases associated with tryptase activity
DE19817461A1 (en) * 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
CN1142912C (en) * 1998-08-04 2004-03-24 阿斯特拉曾尼卡有限公司 Amide derivatives useful as inhibitors of cytokine production
ES2211172T3 (en) * 1998-09-25 2004-07-01 Astrazeneca Ab DERIVATIVES OF BENZAMIDA AND ITS USE AS INHIBITORS OF CYTOKINES.
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
NZ518255A (en) * 1999-09-13 2004-11-26 Boehringer Ingelheim Pharma Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
EP1230349B1 (en) 1999-11-18 2007-06-13 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
PT1309592E (en) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
RU2317988C2 (en) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Substituted pyrazoles, pharmaceutical composition based on thereof, using pharmaceutical composition and method for inhibition of cathepsin s activity
CN1642973A (en) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 A method for treating allergies
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP2004523506A (en) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (en) 2001-03-22 2004-12-15 Dendreon Corp Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
RS19504A (en) 2001-09-14 2007-02-05 Aventis Pharmaceuticals Inc., Novel compounds and compositions as cathepsin inhibitors
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
DK2288615T3 (en) * 2008-05-21 2017-09-04 Genesis Tech Ltd SELECTIVE CASPASE INHIBITORS AND APPLICATIONS THEREOF
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
EP2697246B1 (en) 2011-04-15 2018-03-07 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (en) * 2011-05-06 2013-09-17 연세대학교 산학협력단 Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same
KR101385855B1 (en) * 2012-10-16 2014-04-22 이동익 Diaromatic amino acid-based substrate for detecting cathepsins
CN111601813A (en) * 2018-01-19 2020-08-28 株式会社大阪曹达 Organic silicon compound and rubber composition using same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
TW470750B (en) 2002-01-01
IL117638A0 (en) 1996-07-23
AU713492B2 (en) 1999-12-02
PL322409A1 (en) 1998-01-19
AU5367496A (en) 1996-10-16
NO974403L (en) 1997-11-17
CA2216151A1 (en) 1996-10-03
CZ298197A3 (en) 1998-03-18
KR19980703261A (en) 1998-10-15
ZA962336B (en) 1996-07-31
CN1071751C (en) 2001-09-26
NO311573B1 (en) 2001-12-10
NO974403D0 (en) 1997-09-23
NZ305626A (en) 2000-01-28
WO1996030353A1 (en) 1996-10-03
JPH11503417A (en) 1999-03-26
EP0817778A1 (en) 1998-01-14
CN1184472A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
IL112759A0 (en) Novel cysteine protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
AU5122196A (en) Cysteine protease inhibitor
PL331533A1 (en) Cysteine protease inhibitors
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
NO20006717D0 (en) protease inhibitors
AU7127298A (en) Serine protease inhibitors
PL322409A1 (en) Reversible protease inhibitors
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
EP0602069A4 (en) RETROVIRAL PROTEASE INHIBITORS.
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
EP0975353A4 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
EP0923535A4 (en) Inhibitors of cysteine protease
AU6458396A (en) Phosphorous-containing cysteine and serine protease inhibitors
EP1032393A4 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
IL123771A0 (en) Metal complexes as cysteine protease inhibitors
GB9603217D0 (en) Serine protease inhibitors
NO975534L (en) Imidazo- £ 1.5µ-pyridine-derived serine protease inhibitors
ATE311440T1 (en) BACILLUS PROTEASES
ZA969078B (en) Inhibitors of cysteine protease.
DE69635608D1 (en) BACILLUS PROTEASES
BR9612344A (en) Protease inhibitors
ZA971178B (en) Serine protease inhibitors.
MA23352A1 (en) BLEACHING COMPOSITION COMPRISING PROTEASE ENZYMES
HK1024005A (en) Serine protease inhibitors